Trade Travere Therapeutics, Inc. - TVTX CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.13
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.01)

Key Stats

• Prev. Close: 66.45
• Open: 65.76
• 1-Year Change: 236.54%
• Day's Range: 64.95 - 66.03

Trade Travere Therapeutics, Inc. - TVTX

Travere Therapeutics (TVTX) is a US-based biopharmaceutical company that identifies, develops and delivers life-changing therapies to people suffering from rare diseases. The firm is headquartered in San Diego, California.

The company currently has four approved commercial therapies: Chenodal (chenodiol), Cholbam (cholic acid), Thiola (tiopronin), and Thiola EC (tiopronin) delayed-release tablets.

The rare diseases for which the company currently offers therapies are Peroxisomal Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD), Cerebrotendinous Xanthomatosis (CTX), Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy (IgAN), Classical Homocystinuria (HCU), Cystinuria, Bile Acid Synthesis Disorders (BASD), N-Glycanase 1 (NGLY1) Deficiency, and Alagille Syndrome (ALGS).

Travere Therapeutics shares trade on the NASDAQ Stock Exchange under the ticker symbol TVTX. The company was founded as Retrophin Inc. in February 2011 and became public in December 2012.As of August 2022, Travere Therapeutics does not pay a dividend. 

You can follow the ups and downs of the Travere Therapeutics stock price at Capital.com. Always stay on top of the latest price developments with our live TVTX stock price chart.